QSAR Studies on Drug Transporters Involved in Toxicology

Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals

Volumn , Issue , 2006, Pages 295-314

  Ecker, Gerhard F ^a   Chiba, Peter ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Combinatorial QSAR approach; Drug transporters in toxicology; QSAR approaches to design inhibitors

Indexed keywords

EID: 84889611631     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470145890.ch11     Document Type: Chapter

References (74)

1. Endres CJ, Hsiao P, Chung FS, Unadkat JD. The role of transporters in drug interactions. Eur J Pharm Sci 2006;27:501-17.
2. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000;40:91-8.
3. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-45.
4. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends in Pharmacol Sci 2004;25:423-9.
5. Yu EW, McDermott G, Zgurskaya HI, Nikaido H, Koshland DE Jr. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science 2003;300:976-80.
6. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
7. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by multidrug transporter. An Rev Biochem 1993;62:385-427.
8. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity on vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
9. Leonard GD, Polgar O, Bates SE. ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 2002;3:1652-9.
10. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
11. Raub TJ. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 2006;1:3-25.
12. Pleban K, Ecker GF. Inhibitors of P-glycoprotein-Lead identification and optimisation. Minirev Med Chem 2005;5:153-63.
13. Wiese M, Pajeva IK. Structure-activity relationships of multidrug resistance revers-ers. Curr Med Chem 2001;8:685-713.
14. Tmej C, Chiba P, Huber M, Richter E, Hitzler M, Schaper KJ, Ecker G. A combined Hansch/free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance. Arch Pharm (Weinheim) 1998;331:233-40.
15. Kaiser D, Smiesko M, Kopp S, Chiba P, Ecker GF. Interaction field based and hologram based QSAR analysis of propafenone-type modulators of multidrug resistance. Med Chem 2005;1:431-44.
16. Tmej C, Chiba P, Schaper KJ, Ecker G, Fleischhacker W. Artificial neural networks as versatile tools for prediction of MDR-modulatory activity. Adv Exp Med Biol 1999;457:95-105.
17. Klein C, Kaiser D, Kopp S, Chiba P, Ecker GF. Similarity based SAR (SIBAR) as tool for early ADME profiling. J Comput Aided Mol Des 2002;16:785-93.
18. Ecker G, Chiba P, Hitzler M, Schmid D, Visser K, Cordes HP, Csöllei J, Seydel JK, Schaper KJ. Structure-activity relationship studies on benzofurane analogs of propafenone-type modulators of tumor cell multidrug resistance. J Med Chem 1996;39:4767-74.
19. Chiba P, Ecker G, Schmid D, Drach J, Tell B, Goldenberg S, Gekeler V. Structural requirements for activity of propafenone type modulators in PGP-mediated multidrug resistance. Mol Pharmacol 1996;49:1122-30.
20. Chiba P, Hitzler M, Richter E, Huber M, Tmej C, Ecker G. Studies on propafenone-type modulators of multidrug resistance: III. Variations on the nitrogen. Quant Struct-Act Rel 1997;16:361-6.
21. Ecker G, Huber M, Schmid D, Chiba GF. The importance of a nitrogen atom in modulators of multidrug resistance. Mol Pharmacol 1999;56:791-6.
22. Seelig A, Gatlik-Landwojtowicz E. Inhibitors of multidrug efflux transporters: Their membrane and protein interactions. Minirev Med Chem 2005;5:135-51.
23. Pajeva IK, Wiese M. Molecular modelling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study. J Med Chem 1998;41:1815-26.
24. Pajeva IK, Wiese M. A comparative molecular field analysis of propafenone-type modulators of cancer multidrug resistance. Quant Struct-Act Rel 1998;17:301-12.
25. Globisch C, Pajeva IK, Wiese M. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. Bioorg Med Chem 2006; 14:1588-98.
26. Kaiser D, Bohl M, Kopp S, Chiba P, Ecker GF. A Volsurf model of propafenone-type inhibitors of P-glycoprotein for in silico screening of the Leadquest compound library. Drugs Future 2004;29 (Suppl A):119.
27. Pajeva IK, Wiese M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: Explanation of structural variety (hypothesis). J Med Chem 2002;45:5671-86.
28. Garrigues A, Loiseau N, Delaforge M, Ferte J, Garrigos M, Andre F, Orlowski S. Characterization of two pharmacophores on the multidrug transporter P-glycopro-tein. Mol Pharmacol 2002;62:1288-98.
29. Penzotti JE, Lamb ML, Evensen E, Grootenhuis PD. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 2002;45:1737-40.
30. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz E, Lan LB, et al. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 2002;61:974-81.
31. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, et al. Threedimensional quantitiative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 2002;61:964-73.
32. Langer T, Eder M, Hoffmann RD, Chiba P, Ecker GF. Lead identification for modulators of multidrug resistance based on in silico screening with a pharma-cophoric feature model. Arch Pharm (Weinheim) 2004;337:317-27.
33. Wang YH, Li Y, Yang SL, Yang L. An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network. J Comput Aided Mol Des 2005;19:137-47.
34. Kaiser D, Tmej C, Chiba P, Schaper KJ, Ecker G. Artificial neural networks in drug design: II. Influence of learning rate and momentum factor on the predictive ability. Sci Pharm 2000;68:57-64.
35. Kaiser D, Terfloth L, Kopp S, Chiba P, Gasteiger J, Ecker GF. Artificial neural networks for identification of new modulators of multidrug resistance. In: Sener E, Yalcin I, editors, QSAR & molecular modelling in rational design of bioactive molecules. Computer aided Drug Design & Development Society in Turkey, Antrara, Turkey, 2006, p. 274-7.
36. Chiba P, Ecker GF. Inhibitors of ABC-type drug efflux pumps-An overview on the actual patent situation. Expert Opin Ther Patents 2004;14:499-508.
37. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Canc 2002;2:48-58.
38. van Herwaarden AE, Schinkel AH. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends in Pharmacol Sci 2006;27:10-16.
39. Mao Q, Unadkat JD. Role of breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005;7:E118-33.
40. Zhang S, Yang X, Coburn RA, Morris ME. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 2005;70:627-39.
41. Boumendjel A, Nicolle E, Moraux T, Gerby B, Blanc M, Ronot X, Boutonnat J. Piperazinobenzopyranones and phenylalkylaminobenzopyranones: Potent inhibitors of breast cancer resistance protein (ABCG2). J Med Chem 2005;48:7275-81.
42. van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ. Inhibiton of BCRP-mediated drug efflux by fumitremorgin-type indolyl dikeotpiperazines. Bioorg Med Chem Lett 2001;11:29-32.
43. Cramer J, Kopp S, Bates SE, Chiba P, Ecker GF. Multispecificity of drug transporters: Probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2. Submitted.
44. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 2003;55:3-29.
45. Deeley RG, Cole SPC. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 2006;580:1103-11.
46. Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, Di Pietro A. Anticancer multidrug resistance mediated by MRP1: Recent advances in the discovery of reversal agents. Med Res Rev 2005;25:453-72.
47. Lather V, Madan AK. Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidine. Bioorg Med Chem Lett 2005;15:4967-72.
48. Faber KN, Muller M, Jansen PL. Drug transport proteins in the liver. Adv Drug Deliv Rev 2003;55:107-24.
49. van Zanden JJ, Wortelboer HM, Bijlsma S, Punt A, Usta M, van Bladeren PJ, et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 2005; 69:699-708.
50. Ng C, Xiao YD, Lum BL, Han YH. Quantitative structure-activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2). Eur J Pharm Sci 2005;26:405-13.
51. Iwase K, Hirono S. Estimation of active comformation of drugs by a new molecular superposing procedure. J Comput Aided Mol Des 1999;13:305-15.
52. Hirono S, Nakagome I, Imai R, Maeda K, Kusuhara H, Sugiyama Y. Estimation of the three-dimensional pharmacophore of ligands for rat multidrug-resistance associated protein 2 using ligand-based drug design techniques. Pharm Res 2005; 22:260-9.
53. Hirano H, Kurata A, Onishi Y, Sakurai A, Saito H, Nakagawa H, et al. High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol Pharm 2006;3:252-65.
54. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Investig 2003;33:1-5.
55. Chang C, Pang KS, Swaan PW, Ekins S. Comparative pharmacophore modelling of organic anion transporting polypeptides: A meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 2005;314:533-41.
56. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004;21:25-51.
57. Delie F, Rubas WA. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: Advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Sys 1997;14:221-86.
58. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 1999;88:28-33.
59. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998;251:252-61.
60. Didziapetris R, Japertas P, Avdeef A, Petrauskas A. classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003;11:391-406.
61. Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J Pharm Sci 2004;93:957-68.
62. Cabrera MA, Gonzalez I, Fernandez C, Navarro C, Bermejo M. A topological substructural approach for the prediction of P-glycoprotein substrates. J Pharm Sci 2006;95:589-606.
63. Cartmell J, Enoch S, Krstajic D, Leahy DE. Automated QSPR through competitive workflow. J Comput Aided Mol Des 2005;19:821-33.
64. Kovatcheva A, Golbraikh A, Oloff S, Xiao YD, Zheng W, Wolschann P, et al. A combinatorial QSAR of Ambergris fragrance compounds. J Chem Inf Comput Sci 2004;44:582-95.
65. De Cerqueira Lima P, Golbraikh A, Oloff S, Xiao Y, Tropsha A. Combinatorial QSAR modeling of P-glycoprotein substrates. J Chem Inf Model 2006;46:1245-54.
66. Crivori P, Reinach B, Pezzetta D, Poggesi I. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharm 2006;3:33-44.
67. Cianchetta G, Singleton RW, Zhang M, Wildgoose M, Giesing D, Fravolini A, et al. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. J Med Chem 2005;48:2927-35.
68. Penzotti JE, Lamb ML, Evensen E, Grootenhuis PDJ. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 2002;45:1737-40.
69. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006;34:1976-84.
70. Wang YH, Li Y, Yang SL, Yang L. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model 2005;45:750-7.
71. Xue Y, Yap CW, Sun LZ, Cao ZW, Wang JF, Chen YZ. Prediction of P-glyco-protein substrates by a support vector machine approach. J Chem Inf Comput Sci 2004;44:1497-505.
72. Adenot M, Lahana R. Blood-brain barrier permeation models: Discrimination between potential CNS and non-CNS drugs including P-glycoprotein substrates. J Chem Inf Comput Sci 2004;44:239-48.
73. Arodz T, Yuen DA, Dudek AZ. Ensemble of linear models for predicting drug properties. J Chem Inf Model 2006;46:416-23.
74. Schmid D, Ecker G, Richter E, Hitzler M, Chiba P. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol 1999;58:1447-56.